Approval First Then Everything
The bottom line: For now, the powerful drugs being tested as medicine — like MDMA and psilcybin (the active part of magic mushrooms) — stay on the government's most banned list until the FDA, the agency that decides if a medicine is safe, says yes. Congress is very unlikely to change those rules this year on its own. So if you're waiting for these treatments, the real door is FDA approval, and everything else follows from it.
What happened today is mostly about patience and order. The strongest reading from the data is simple: lawmakers in Washington will not move ahead of the FDA. One legislator put it plainly — they can't get out in front of the science, because without the FDA's stamp, the votes aren't there and the political danger is too high. At the same time, the most likely path for MDMA as a treatment for PTSD (the lasting fear and pain people carry after trauma) is approval — but a careful one. That means if it's cleared, it would come with strict rules: doctors watching over every dose in a clinic, not pills sent home. The market echoed this calm. The bigger companies, Compass and Atai, rose slightly (up about 2.4% and 2.5%), while MindMed slipped (down 3.7%). Investors are starting to separate the steady players from the shaky ones.
Beneath the news is a single thread: order is winning over speed. There's a real argument happening — are we moving too slowly and letting people suffer, or moving too fast and risking mistakes? The answer forming in the data is neither extreme. It's a middle road. Approval is coming, but with guardrails. And a quieter compromise is taking shape too: instead of changing the law for everyone, lawmakers may carve out a special path for veterans first. That's the deeper current — not a sudden flood of legal psychedelics, but a careful, narrow opening that proves the treatment works before it widens. The highest path here is not the fastest one. It's the one that holds, the one that doesn't collapse under a single bad headline.
For the people inside this story, the wait is the hardest part. A veteran who has tried every approved option and still wakes at 3 a.m. inside the same nightmare does not feel the difference between "soon" and "careful." A spouse watching them struggle just wants the door to open. The honest truth is that it is opening — slowly, deliberately — and the slowness is partly what will make it last. A treatment approved with strong safety rules is one that survives, that insurance might one day cover, that a doctor in an ordinary town could offer without fear. There's also a worry worth naming: that even when these treatments arrive, they could cost so much that only the wealthy reach them. That concern is real, and the fact that people are already raising it loudly is itself a kind of protection. The best thing that could genuinely happen from here is not a miracle overnight. It's a real medicine, proven and protected, reaching the people who have waited longest — starting with those who served.
What is being called in cannot be called back. The currents forming in legislation, in research, in culture — OOTW reads them daily, so you don't have to navigate them alone.
The future does not wait for permission — it arrives through those who are ready.
85%
Psilocybin and MDMA stay on the US banned list through 2025
The DEA (Drug Enforcement Administration, the US agency that controls which drugs are legal) cannot move psilocybin or MDMA off the most restricted category unless the FDA (the US drug regulator) first approves them as medicine. Since no FDA approval exists yet, the legal status stays frozen. This means anyone caught with these substances still faces serious federal criminal consequences.
→ Because no FDA approval exists to trigger the process, psilocybin and MDMA will almost certainly remain federally banned through the end of 2025.
Resolves: 2026-12-31 · USA
REGULATORY
the precise call ▾
DEA does not reschedule psilocybin or MDMA out of Schedule I before 2026-12-31.. DEA rescheduling is procedurally gated on completed FDA approval plus an HHS abuse-potential review. With no FDA approval in hand, the statutory trigger for the eight-factor review is absent, so Schedule I status holds.
78%
MDMA therapy for trauma will not get US approval by end of 2025
In August 2024, the FDA (the US drug regulator) rejected the first application to approve MDMA as a treatment for PTSD (post-traumatic stress disorder). The agency had concerns about participants knowing they were on the real drug, the potential for abuse, and problems with how the trials were run. To reapply, the company needs to run new large-scale trials, which will take years.
→ MDMA therapy for PTSD will almost certainly not be federally approved before 2026 — the FDA said no, and fixing the problems takes years.
Resolves: 2026-12-31 · USA
REGULATORY
the precise call ▾
No FDA approval of MDMA-assisted therapy for PTSD occurs before 2026-12-31.. After the August 2024 FDA rejection of Lykos's MDMA-PTSD application citing unresolved unblinding, abuse-potential, and trial-conduct concerns, a new application requires additional Phase 3 data unlikely to complete and clear review within this timeframe. No approval is the base case.
74%
Any approved psychedelic therapy must happen in a monitored clinic
If MDMA or psilocybin ever gets FDA approval, the agency will almost certainly attach strict rules requiring patients to take the drug inside a licensed clinic while staff watch over them the whole time. These rules, called a REMS (Risk Evaluation and Mitigation Strategy), are how the FDA manages especially risky medicines. You would not be able to take an approved psychedelic therapy at home.
→ If psychedelic medicines get approved, the government will almost certainly require every dose to be taken in a supervised clinic — no home use, no uncertified providers.
Resolves: 2027-12-31 · USA
REGULATORY
the precise call ▾
Any FDA approval of an MDMA or psilocybin therapy through 2027-12-31 includes a REMS mandating monitored in-clinic dosing sessions.. Unresolved abuse-potential and the requirement for supervised administration during psychoactive sessions make a restrictive REMS with mandatory monitored dosing the only defensible regulatory path; a label without such controls is implausible given prior FDA signals.
80%
US Congress will not pass a law legalizing these drugs by 2025
For Congress to reschedule psilocybin or MDMA, politicians would need to vote for it openly, without FDA approval giving them political cover. With midterm elections looming, most lawmakers see that vote as too risky. The result is that no new federal law changing the status of these drugs is likely to pass.
→ Congress is extremely unlikely to pass any law rescheduling psychedelics before the end of 2025 — the political conditions simply are not there.
Resolves: 2026-12-31 · USA
LEGISLATION
the precise call ▾
No federal legislation rescheduling psilocybin or MDMA is enacted in the 119th Congress before 2026-12-31.. Without FDA approval providing political cover, floor votes lack the coalition needed, and broad rescheduling carries high electoral risk in a midterm year. No standalone enacted statute is the likely outcome.
80%
A key flaw in psychedelic drug trials will keep making headlines
In psychedelic studies, participants almost always know whether they got the real drug or a placebo because the experience is so powerful and obvious. This is called 'functional unblinding,' and it makes it hard to know if the benefits come from the drug or from people simply expecting to feel better. Regulators and scientists are increasingly calling this out as a problem that no one has solved yet.
→ The fact that people always know they took the real drug is a fundamental problem in psychedelic research, and it will keep blocking or delaying approvals until someone solves it.
Resolves: 2027-06-30 · Global
RESEARCH
the precise call ▾
Functional unblinding is cited as an unresolved limitation in at least one FDA advisory committee or major peer-reviewed publication on psychedelic trials before 2027-06-30.. No current trial design eliminates expectancy effects from psychoactive blinding failure, and this critique was central to the 2024 FDA advisory rejection; it will continue to appear in regulatory and scientific discussion.